Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery.

Teijin Signs Agreement for SanBio’s New Drug for Stroke Therapy – Major Entry into Regenerative Medicine Market.

« 前ページへ